Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide in Pediatric Sepsis
NCT01573806Phase 2Withdrawn
- Sponsor
- Seattle Children's
- Start
- Oct 2012
- Primary completion
- Oct 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in septic shock comparing Exenatide with Exenatide vehicle (2 arms). Primary endpoints: Exenatide associated adverse event occurence and Area under the exenatide concentration curve at 48 hours. Planned start Oct 2012; status: withdrawn.
02
Drugs
exenatide
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT01573806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01573806.